Research programme: bispecific antibody-drug conjugates - Genmab/Unknown

Drug Profile

Research programme: bispecific antibody-drug conjugates - Genmab/Unknown

Alternative Names: bispecific antibody-drug conjugate; DuoBody-ADC

Latest Information Update: 19 Feb 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genmab
  • Class Bispecific antibodies; Drug conjugates
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 30 Sep 2013 Preclinical trials in Solid tumours in Denmark (Parenteral)
  • 23 Dec 2011 Early research in Solid tumours in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top